Research Papers

Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV status

Publication: BMC Pulmonary Medicine

Author(s): Conor D. Tweed, Angela M. Crook, Rodney Dawson, Andreas H. Diacon, Timothy D. McHugh, Carl M. Mendel, Sarah K. Meredith, Lerato Mohapi, Michael E. Murphy, Andrew J. Nunn, Patrick P. J. Phillips, Kasha P. Singh, Melvin Spigelman, Stephen H. Gillespie

8/2019

Tags: Clinical Trial Results, ReMoxTB

Gender differences in tuberculosis treatment outcomes: a post hoc analysis of the REMox TB study

Publication: BMC Medicine (2018) 16:189

Author(s): Murphy, M.; Wills, G; Murthy, S.; Louw, C.; Bateson, A.; Hunt, R.; McHugh, T.; Nunn, A.; Meredith, S.; Mendel, C.; Spigelman, M.; Crook, A.; Gillespie, S.

10/2018

Tags: ReMoxTB

Toxicity associated with tuberculosis chemotherapy in the REMoxTB study

Publication: BMC Infectious Diseases

Author(s): Tweed, Conor D., Crook, Angela M. Amukoye, Evans I. Dawson, Rodney Diacon, Andreas H. Hanekom, Madeline McHugh, Timothy D. Mendel, Carl M. Meredith, Sarah K. Murphy, Michael E. Murthy, Saraswathi E. Nunn, Andrew, Spigelman, M.

7/2018

Tags: Clinical Trial Results, ReMoxTB

Pretreatment chest x-ray severity and its relation to bacterial burden in smear positive pulmonary tuberculosis.

Publication: BMC Medicine

Author(s): Murthy S., Chatterjee F., Crook A., Dawson R., Mendel C., Murphy M., Murray S., Nunn A., Phillips P., Singh K., McHugh T., Gillespie S.

5/2018

Tags: ReMoxTB

Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study

Publication: BMC Medicine

Author(s): Tweed C, Mendel, C. Murray, S.,Gillespie, S., Crook, A.,et al.

3/2018

Tags: Moxifloxacin, ReMoxTB

A comparison of liquid and solid culture for determining relapse and durable cure in phase III TB trials for new regimens

Publication: BMC Medicine 2017 15:207

Author(s): Patrick P. J. Phillips, Carl M. Mendel, Andrew J. Nunn, Timothy D. McHugh, Angela M. Crook, Robert Hunt, Anna Bateson and Stephen H. Gillespie

12/2017

Tags: Clinical Trial Results, ReMoxTB

Spot sputum samples are at least as good as early morning samples for identifying Mycobacterium tuberculosis

Publication: BMC Medicine 2017 15:207

Author(s): Patrick P. J. Phillips, Carl M. Mendel, Andrew J. Nunn, Timothy D. McHugh, Angela M. Crook, Robert Hunt, Anna Bateson and Stephen H. Gillespie

12/2017

Tags: Clinical Trial Results, ReMoxTB

Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials

Publication: Phillips PPJ, Mendel CM, Burger DA, et al. Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials. BMC Medicine. 2016 Mar.14:19. doi: 10.1186/s12916-016-0565-y

3/2016

Tags: Biomarkers, Clinical Development, Moxifloxacin, ReMoxTB, Trial Design

Evaluation of moxifloxacin-containing regimens in pathologically distinct murine tuberculosis models

Publication: Li SY, Irwin SM, Converse PJ, Mdluli KE, Lenaerts AJ, Nuermberger EL. Evaluation of moxifloxacin-containing regimens in pathologically distinct murine tuberculosis models. Antimicrob Agents Chemother. 2015 Jul;59(7):4026-30. doi: 10.1128/AAC.00105-15.

4/2015

Tags: Clinical Development, HRZE, Moxifloxacin, Preclinical Data, Preclinical Models, ReMoxTB

Shorter moxifloxacin-based regimens for drug-sensitive tuberculosis

Publication: Alffenaar JW, Gumbo T, Aarnoutse R. Shorter moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med. 2015 Feb 5;372(6):576. doi: 10.1056/NEJMc1414718#SA1.

2/2015

Tags: Clinical Development, Clinical Trial Results, HRZE, Moxifloxacin, ReMoxTB

Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis

Publication: Gillespie SH, Crook AM, McHugh TD, et. al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med. 2014 Oct 23;371(17):1577-87. doi: 10.1056/NEJMoa1407426.

4/2014

Tags: Clinical Development, Clinical Trial Results, HRZE, Moxifloxacin, ReMoxTB

Whole-genome sequencing to establish relapse or re-infection with Mycobacterium tuberculosis: a retrospective observational study.

Publication: Lancet Respiratory Medicine

Author(s): Bryant J, Harris S, Parkhill J, Dawson R, Diacon A, van Helden P, Pym A, Mahayiddin A, Chuchottaworn C, Sanne I, Louw C, Boeree M, Hoelscher M, McHugh T, Bateson A, Hunt R, Mwaigwisya S, Wright L, Gillespie S, Bentley, S.

12/2013

Tags: M.tb. Biology, ReMoxTB